Abstract 5801
Background
Malignant tumors represent a major public health problem in the world and Mexico is not the exception. The development of Population-Based Cancer Registries (PBCR) that collect cancer cases in a determined locality and help evaluate health programs is fundamental. In Mexico there were only a couple of attempts on hospital and histopathological registries, reason why it was decided to implement a PBCR, named as the National Network of Cancer Registries (NNCR).
Methods
During the creation process, support was received from the International Agency of Research in Cancer (IARC), through the Global Initiative for Cancer Registry Development. The NNRC is operated in a central level located in Mexico City, and the cases in the sources of information established are registered in a national registration form composed of 29 variables structured and standardized according to international guidelines. The collection and administration of information is done through a technological system, called RedCancerMX in a mobile and web application hosted on the cloud.
Results
In 2016, the General Health Law was modified to create the National Cancer Registry and in 2017 it was approved. In July 2018 the regulations of the NNCR are published, which establishes the bases for organization, integration and coordination. To the date, the NNCR is active in 8 cities, reaching 10% of national coverage. The process of integration of each city to the NNCR, included a feasibility analysis, validation and training. The process of obtaining data covers subprocesses of collection, validation and authorization carried out by medical specialists. RedCancerMX had integrated 11 validations established by international organizations to guarantee the quality of the information and they are aligned to quality indicators proposed by the IARC: comparability, validity, timeliness and completeness.
Conclusions
In Mexico, the NNCR is already established, which is considered an epidemiological surveillance system with national, active and continuous validity. This NNCR will allow us to determine the incidence of cancer and survival rates in the Mexican population, helping to implement new and better strategies for cancer control.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Instituto Nacional de Cancerología.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3973 - A randomized phase II study on the OPTimization of IMmunotherapy in squamous carcinoma of the head and neck (SCCHN) – OPTIM (AIO-KHT-0117)
Presenter: Viktor Grünwald
Session: Poster Display session 3
Resources:
Abstract
3489 - Overall Survival (OS) and Metastasis-Free Survival (MFS) in men with Biochemically Relapsed (BCR) Prostate Cancer after radical prostatectomy (RP) managed with deferred Androgen Deprivation Treatment (ADT): A combined Johns Hopkins and CPDR study
Presenter: Catherine Marshall
Session: Poster Display session 3
Resources:
Abstract
4606 - ARCHES – the role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analyses of high and low disease volume and risk groups
Presenter: Arnulf Stenzl
Session: Poster Display session 3
Resources:
Abstract
2975 - Updated survival analyses of a multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) (CHEIRON study).
Presenter: Orazio Caffo
Session: Poster Display session 3
Resources:
Abstract
2708 - Real-world analysis of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving vs not receiving chemotherapy in the treatment sequence
Presenter: Alicia Morgans
Session: Poster Display session 3
Resources:
Abstract
2134 - Baseline fracture risk in men with prostate cancer starting the STAMPEDE trial
Presenter: Janet Brown
Session: Poster Display session 3
Resources:
Abstract
3504 - Risk of falls and fractures in patients with castration resistant prostate cancer (CRPC) treated with new hormonal agents – a meta-analysis of randomized controlled trials.
Presenter: Rodrigo Coutinho Mariano
Session: Poster Display session 3
Resources:
Abstract
2342 - Pain progression at initiation of chemotherapy in metastatic Castration-Resistant Prostate Cancer (mCRPC) is associated with a poor prognosis: a post-hoc analysis of FIRSTANA
Presenter: Nicolas Delanoy
Session: Poster Display session 3
Resources:
Abstract
5331 - Pain evaluation in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) in the PARABO observation study
Presenter: Holger Palmedo
Session: Poster Display session 3
Resources:
Abstract
2823 - Time to castration resistant prostate cancer (CRPC) and the risk of developing immune disorders
Presenter: Vincenza Conteduca
Session: Poster Display session 3
Resources:
Abstract